Boston Scientific Neuromodulation Corporation

What Boston Scientific Neuromodulation Corporation does

Boston Scientific Neuromodulation Corporation is a wholly-owned subsidiary of Boston Scientific Corporation (NYSE: BSX), a global medical device company headquartered in Marlborough, Massachusetts, with operational presence in the United States (Valencia, California neuromodulation operations), the broader Americas, Asia Pacific (China, India, Japan, Korea, Australia), and Europe (Germany, Spain). The company's neuromodulation portfolio centers on three platforms: Deep Brain Stimulation (Vercise Genus with Illumina 3D image-guided programming and FDA-approved 16-contact directional leads), Spinal Cord Stimulation (WaveWriter Alpha with FAST therapy and MRI-conditional adapters), and Basivertebral Nerve Ablation (Intracept, a purpose-built system for vertebrogenic pain). The November 2024 acquisition of Axonics for $3.7 billion extended the franchise into sacral neuromodulation for overactive bladder, fecal incontinence, and urinary retention, with further M&A in 2025 (Nalu Medical, SoniVie, previously Lumenis surgical and Valencia Technologies).

The broader Boston Scientific portfolio spans 15 medical specialties, including electrophysiology (FARAPULSE Pulsed Field Ablation, WATCHMAN FLX Pro left atrial appendage closure, HeartLogic heart failure diagnostic), interventional cardiology (SENTINEL Cerebral Protection, AGENT drug-coated balloon), gastroenterology (EXALT single-use scopes, SpyGlass DS direct visualization, ERCP portfolio), interventional oncology (TheraSphere Y-90 microspheres), urology (Rezum, GreenLight, LithoVue), and vascular surgery (ENROUTE, SEISMIQ, Varithena). Enabling technologies include the OPAL HDx high-density mapping system, LATITUDE NXT remote patient management, ImageReady MRI conditional technology, and the EDUCARE medical education platform.

The business model is enterprise hardware sales to healthcare providers (hospitals, clinics, and physicians) through a direct field sales force, e-commerce ordering platform (ecommerce.bostonscientific.com), and 1-888 customer care. Revenue mechanics are quote-based with no public pricing disclosure. GTM combines enterprise field sales, event-driven adoption through medical conferences and EDUCARE physician training, and community-led demand generation via patient education websites (Pain.com, ChooseYou, EDCure, FixIncontinence, TreatMyBPH, MyKidneyStone) that build therapy awareness and drive physician referrals. Customer segments include healthcare professionals, patients and caregivers, and healthcare administrators managing reimbursement, coding, and operational efficiency.

Name

Boston Scientific Neuromodulation Corporation

Legal name

Boston Scientific Corporation

Website

https://bostonscientific.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Boston Scientific Neuromodulation Corporation, a subsidiary of Boston Scientific Corporation (NYSE: BSX), develops and markets implantable neuromodulation devices (DBS, SCS, sacral neuromodulation) and a broader medical device portfolio across 15 specialties for healthcare providers and patients globally.

Ownership category

akta.pro rank

Product category

Neuromodulation and Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Pain Management (Spine & Musculoskeletal) (HLAKALAM)

Keywords

• Implantable medical devices
• Neuromodulation systems
• Cardiac rhythm management
• Interventional oncology devices
• Minimally invasive therapies

Headquarters

HQ city

Valencia

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Sale of medical devices and implants to healthcare providers including hospitals, clinics, and physicians across 15 medical specialty areas including neuromodulation, cardiology, gastroenterology, and urology

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Boston Scientific Neuromodulation Corporation designs, manufactures, and sells implantable medical devices for neuromodulation, cardiac rhythm management, interventional cardiology, endoscopy, interventional oncology, structural heart, urology, and pelvic health. The core portfolio includes Deep Brain Stimulation (Vercise Genus), Spinal Cord Stimulation (WaveWriter Alpha), Basivertebral Nerve Ablation (Intracept), Sacral Neuromodulation (Axonics), Pulsed Field Ablation (FARAPULSE), and Left Atrial Appendage Closure (WATCHMAN FLX Pro) systems sold to hospitals, clinics, and physicians across 15+ medical specialties.

Product overview

Boston Scientific Neuromodulation Corporation offers a comprehensive neuromodulation and medical device portfolio organized around multiple therapy areas. The core neuromodulation division provides Deep Brain Stimulation (Vercise Genus System with Illumina 3D programming), Spinal Cord Stimulation (WaveWriter Alpha with FAST Therapy), and Basivertebral Nerve Ablation (Intracept Procedure). Following the $3.7B acquisition of Axonics in November 2024, the company expanded into sacral neuromodulation for pelvic health conditions including overactive bladder and fecal incontinence. The portfolio spans 16 medical specialties including Electrophysiology (FARAPULSE PFA System, WATCHMAN FLX Pro, cardiac monitors, ICDs, CRT devices), Interventional Cardiology (SENTINEL Cerebral Protection, drug-coated balloons), Heart Failure (HeartLogic Diagnostic, LATITUDE Remote Monitoring), Gastroenterology (EXALT single-use scopes, SpyGlass, ERCP portfolio), Interventional Oncology (TheraSphere Y-90, EMBOLD coils), Vascular Surgery (ENROUTE, SEISMIQ, Varithena), Pain Management (SCS systems, RF ablation), Urology (Rezum, GreenLight laser, LithoVue), and Pelvic Health (Bulkamid, Axonics SNM, Upsylon mesh). The company also offers enabling technologies including the OPAL HDx Mapping System, EDUCARE medical education platform, LATITUDE NXT remote patient management, and ImageReady MRI conditional technology across applicable devices.

Differentiator

Problem solved

Functional benefit

Brands

• Vercise Genus: Deep Brain Stimulation (DBS) System for neurological conditions including Parkinson's disease
• WaveWriter Alpha
• Intracept
• Axonics
• FARAPULSE
• WATCHMAN
• HeartLogic
• SpyGlass
• Endura

Products and services

• Vercise Genus Deep Brain Stimulation System Deep brain stimulation system featuring the first and only FDA-approved 16-contact Vercise Cartesia X and Cartesia HX Directional Leads for movement disorder therapy targeting.
• WaveWriter Alpha Spinal Cord Stimulator System Spinal cord stimulator system featuring FDA-approved MRI conditional adapters in SCS, delivering FAST (Fast-Acting Sub-perception Therapy) for paresthesia-free chronic pain relief.
• Intracept Basivertebral Nerve Ablation System The only clinically proven, purpose-built system for vertebrogenic pain relief through intraosseous basivertebral nerve ablation, providing sustained pain and function improvements for 5+ years after a single treatment.
• Axonics Sacral Neuromodulation System Sacral neuromodulation system for treating overactive bladder, fecal incontinence, and urinary retention. Available in both rechargeable and recharge-free configurations.
• FARAPULSE Pulsed Field Ablation System Pulsed field ablation system for isolation of pulmonary veins in patients with drug-refractory atrial fibrillation, featuring selective myocardial ablation to reduce risk of damage to surrounding tissue.
• OPAL HDx Mapping System High-density cardiac mapping system providing integrated mapping for both RF and pulsed field ablation procedures, enabling enhanced access to FARAPULSE PFA System capabilities.
• WATCHMAN FLX Pro Left Atrial Appendage Closure Device FDA-approved device for reducing thromboembolism risk from the left atrial appendage in non-valvular atrial fibrillation patients, featuring HEMOCOAT technology to enhance healing.
• RESONATE HF CRT-D Cardiac resynchronization therapy defibrillator featuring HeartLogic heart failure diagnostic, ImageReady MR-conditional technology, and EnduraLife battery technology for comprehensive heart failure management.
• EMBLEM MRI S-ICD System Subcutaneous implantable cardioverter-defibrillator providing sudden cardiac death protection without touching the heart, vasculature, or substernal space.
• EXALT Model B Single-Use Bronchoscope Single-use bronchoscope specifically designed and optimized for bedside procedures in ICU settings, featuring powerful suction capabilities and familiar handling with sterile single-use convenience.
• TheraSphere Y-90 Glass Microspheres Proven HCC tumor therapy since 1999, designed for control to achieve durable outcomes and reproducible results in radioembolization treatment of liver cancer.
• SENTINEL Cerebral Protection System Cerebral protection system clinically shown to capture and remove debris during TAVR procedures, reducing stroke risk with demonstrated 21% relative risk reduction in all stroke.
• Bulkamid Urethral Bulking System Urethral bulking agent for treating stress urinary incontinence, providing a minimally invasive treatment option.
• LUX-Dx II+ Insertable Cardiac Monitor Insertable cardiac monitor system using enhanced dual-stage algorithms that detect and verify data before sending results for improved arrhythmia monitoring.
• HeartLogic Heart Failure Diagnostic Heart failure diagnostic tool using multiple sensors to proactively alert clinicians via the LATITUDE NXT Remote Patient Management System for early detection of heart failure decompensation.
• SpyGlass DS System Direct visualization system for biliary and pancreatic disease diagnosis and treatment during ERCP procedures.
• Rezum Water Vapor Therapy Minimally invasive water vapor therapy for treating benign prostatic hyperplasia (BPH), offering lasting relief through targeted treatment.
• GreenLight XPS Laser Therapy System Laser therapy system for BPH treatment, providing versatile and innovative treatment options for prostate health.
• LithoVue Elite System Digital flexible ureteroscopy system for kidney stone procedures, providing visualization and diagnostic capabilities.
• SpaceOAR Hydrogel Hydrogel spacer for prostate cancer radiation therapy, designed to protect surrounding tissues during treatment.
• EXALT Model D Single-Use Duodenoscope Single-use duodenoscope for ERCP procedures, addressing infection prevention in endoscopic procedures.

Quantifiable outcome

• 21% relative risk reduction in all stroke and 60% relative risk reduction in disabling stroke through 72 hours with SENTINEL Cerebral Protection System
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core.

• Nalu Medical, Inc.coreStrategic or Co-development Partner · 17 October 2025Boston Scientific announced agreement to acquire Nalu Medical, expanding pain management portfolio with neurostimulation systems for chronic pain treatment.
• SoniVie Ltd.coreStrategic or Co-development Partner · 3 March 2025Boston Scientific announced agreement to acquire SoniVie Ltd., developer of TIVUS (Intravascular Ultrasound System) for renal denervation, expanding structural heart portfolio for hypertension treatment.
• Axonics, Inc.coreStrategic or Co-development Partner · 15 November 2024Boston Scientific completed its $3.7 billion acquisition of Axonics, Inc., expanding its urology offerings with Axonics' neuromodulation systems for sacral neuromodulation treatment of overactive bladder, fecal incontinence, and urinary retention. The deal involved significant leadership changes at Axonics and is aligned with Boston Scientific's growth strategy through mergers and acquisitions.
• Lumenis Ltd.coreStrategic or Co-development PartnerBoston Scientific acquired the global surgical business of Lumenis Ltd., expanding its gynecology and otolaryngology laser portfolio with CO2 laser systems, fibers and accessories for individualized patient care.
• Valencia TechnologiescoreStrategic or Co-development PartnerValencia Technologies became part of Boston Scientific, providing eCoin tibial nerve stimulation technology for overactive bladder and urinary incontinence treatments.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Saluda Medical: Closed-loop evoked-response SCS developer (Evoke system) — emerging competitor with FDA approval bringing objective dosing into SCS, directly challenging WaveWriter Alpha's positioning.
• Inspire Medical Systems: Implantable neurostimulation for obstructive sleep apnea (hypoglossal nerve stimulation) — an emerging neuromodulation franchise that competes for the same payer budgets and physician training slots.
• iRhythm Technologies: Continuous cardiac monitoring via the Zio patch — competes directly with Boston Scientific's LUX-Dx II+ insertable cardiac monitor and BodyGuardian remote cardiac monitor in the same diagnostic cardiology channel.

Direct peers

• Abbott Laboratories: Inherited DBS and SCS businesses (Infinity, Proclaim) plus structural heart (Portico, Tendyne) and diagnostics through the St. Jude and Alere acquisitions, competing across nearly identical therapy areas.
• Medtronic plc: Most direct competitor across neuromodulation (Activa DBS, Vanta/Intellis SCS, InterStim sacral neuromodulation), cardiac rhythm, structural heart, and endoscopy — directly comparable across nearly every Boston Scientific franchise.
• Nevro Corp: Pure-play spinal cord stimulation specialist (Senza, HFX platform with 10 kHz therapy) — a focused SCS competitor targeting the same chronic pain patients that use WaveWriter Alpha.

Others

• Integer Holdings Corporation: Contract manufacturer of active implantable devices (pacemakers, ICDs, neuromodulation leads) — strategic supplier and adjacent participant in the same device manufacturing ecosystem.

Broad incumbents

• Johnson & Johnson (MedTech): MedTech division spans cardiology (Shockwave), orthopedics, and surgery — broad overlap in cardiac, endoscopy, and procedural device categories.
• Stryker Corporation: Diversified medical device incumbent with overlap in endoscopy, interventional technologies, and spine — competes broadly for hospital capital and procedural budgets.
• Edwards Lifesciences: Structural heart leader (Sapien TAVR, Pascal) competing with Boston Scientific's ACURATE and SENTINEL; overlapping portfolios in heart failure and interventional cardiology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/bostonscientific
• LinkedInlinkedin.com/company/boston-scientific

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Scientific Neuromodulation Corporation